European Journal of Medical Research - Deutsche AIDS ...

More documents

Recommendations

Info

June 27, 2007 EUROPEAN JOURNAL OF MEDICAL RESEARCH 103 D.60 (Poster) Lipid profile, cardiovascular risk factors and metabolic syndrome in a group of Brazilian outpatients Silva E. 1 , Bassichetto K.C. 2 , Lewi D.S. 1 1 HIV Treatment & Clinical Research Unit, Federal University of São Paulo, São Paulo, Brazil, 2 Department of Municipality Health of the City of São Paulo, São Paulo, Brazil Objectives: Evaluation of the lipid profile, cardiovascular risk factors using the Framingham score and the metabolic syndrome of the people living with HIV/aids that receive or not antiretroviral therapy attended at the clinics of the Federal University of São Paulo and in the Ambulatory of the Secretary of Health of the city of São Paulo. Methods: During 18 months 319 patients were selected. Results: We included 243 patients with antiretroviral therapy and 76 naïve patients. The median age was 39,7 years and 60,9% of the patients were male. The major cardiovascular risk factors in this population were: 26,8% smoking, 19,2% hypertension, 4,0% diabetes, 40,2% of familiar history of aterosclerosis. In the lipid profile the median of the total cholesterol (205 x 108 mg/dL), HDL-c (51 x 43 mg/dL) and triglycerides (219 x 164 mg/dL) were higher in the group with antiretroviral therapy. According to the Framingham equation, 88,6% and 95,9% of the patients in the group 1 and 2 respectively has a low risk of cardiovascular disease. The metabolic syndrome was present in 12,6% of the patients with antiretroviral therapy and in 11,6% (p=0,832) in the naïve group. Conclusion: The median of total cholesterol, HDL-c, triglycerides were higher in the group with antiretroviral therapy. The cardiovascular risk was low in the two groups according to the Framingham score. The presence of metabolic syndrome was analogous in both groups. D.61 (Vortrag) Increase of susceptibility to Atazanavir (ATV) and Saquinavir (SQV) in multidrug-resistant HIV-1 infected patients carrying Protease-Inhibitor (PI) mutation L76V Braun P. 1 , Walter H. 2 , Däumer M. 3 , Ehret R. 1 , Korn K. 2 , Kaiser R. 3 , Thiele B. 4 , Berg T. 5 , Stürmer M. 6 , Hower M. 7 , Knechten H. 1 , Wiesmann F. 1 1 PZB Aachen, Aachen, Germany, 2 Universität Erlangen, Erlangen, Germany, 3 Universität Köln, Köln, Germany, 4 Institut für Immunologie, Kaiserslautern, Germany, 5 MedLab Berlin, Berlin, Germany, 6 Universität Frankfurt, Frankfurt, Germany, 7 ID-Ambulanz Dortmund, Dortmund, Germany Background: L76V is a rarely observed mutation in clinical isolates of HIV-1 infected patients (pts) with increasing prevalence from 0.17%-1.5% (1998-2005). It is selected under Lopinavir-(LPV), Amprenavir-(APV) and possibly Darunavir-containing treatment and is associated with strong resistance against these drugs. It is furthermore discussed to confer increased susceptibility to ATV and SQV Our objevtive was to elucidate the clinical implication of the L76V mutation in the response to PI-containing regimen in pts with strongly limited therapy options. Methods: Virological, immunological and genotypical data of 30 therapy-experienced, HIV-1 multiclass-resistant, L76V- positive pts were obtained retrospectively. 24 pts were threeclass resistant and 6 showed NRTI- and PI-resistance. 11 pts started a new regimen containing boosted ATV and/or SQV (Group A). 10 pts switched to ATV or SQV plus LPV or APV to maintain selection pressure on L76V (Group B); and 9 pts received LPV or APV regimens (Group C). 26 pts received an optimized backbone therapy, mostly NRTI. Viral-load (VL) and CD4-counts were determined at baseline, and week 12- 96. Success of therapy was defined as VL-reduction
104 EUROPEAN JOURNAL OF MEDICAL RESEARCH June 27, 2007 9100), 138 ng/mL (14 - 518) and 335 ng/mL (60 - 4890). Median (range) cell / serum ratios for LPV, RTV and SQV were 0,06 (0,00 - 1,64), 0,21 (0,00 - 4,64) and 5,16 ( 0,92 - 17,95). Intracellular SQV concentrations were highly associated with serum SQV levels (p
Page 1 and 2:
European Journal of Medical Researc
Page 3 and 4:
Instructions to Authors 1. The Euro
Page 6 and 7:
June 27, 2007 EUROPEAN JOURNAL OF M
Page 8 and 9:
Page 10 and 11:
Page 12 and 13:
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61: June 27, 2007 EUROPEAN JOURNAL OF M
show all

European Journal of Medical Research - Deutsche AIDS ...

Create successful ePaper yourself

Delete template?

Save as template?